

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/505		A1	(11) International Publication Number: WO 99/53923 (43) International Publication Date: 28 October 1999 (28.10.99)
(21) International Application Number: PCT/AU99/00294		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 20 April 1999 (20.04.99)			
(30) Priority Data: PP 3107 22 April 1998 (22.04.98) AU			
(71) Applicant (<i>for all designated States except US</i>): SOLTEC RESEARCH PTY. LTD. [AU/AU]; 8 Macro Court, Rowville, VIC 3178 (AU).		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): WAI-CHIU SO, Tony [AU/AU]; 7 Marsden Crescent, Doncaster East, VIC 3109 (AU). DEO, Peter, Paul [AU/AU]; 3/119 Atkinson Street, Oakleigh, VIC 3166 (AU). TAIT, Russell, John [AU/AU]; 33 Campbell Road, Deepdene, VIC 3103 (AU).			
(74) Agents: NOONAN, Greg et al.; Freehills Patent Attorneys, Level 47, 101 Collins Street, Melbourne, VIC 3000 (AU).			
(54) Title: PHARMACEUTICAL COMPOSITION			
(57) Abstract			
<p>A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5 % by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10 % by weight.</p>			